Yes, I have averaged @45 today valuation of 3.2 billion dollars.
OYO Seeks $400 Mn Funding From Malaysia’s Sovereign Fund Khazanah At $6 Bn Valuation
Problem with OYO is that it’s very hard for them to control there partner’s hotel.
They just cancel the OYO order.
Anyways they are focusing on spritual places.They are also capturing ayodhya market with 65 new hotels.

Unlisted Stock Opportunity I Buy before IPO I Rakesh Bansal

Very informative conversation. Honourable minister Hardeep Puri is a very good speaker and along with Mr Nitin Gadkari , they seem to have a lot of ideas which they would like to implement. Whatever may be their qualifications, they are knowledgeable well informed on the subject especially related to different modes of alternate fuels for Automobiles.technology.

He has covered all topics on emerging trends in automotive technology – starting from CNG, BCG, Ethanol blending program, EV , Electrolysers , renewables- solar ,wind on shore and off shore.

On Green hydrogen, he says given a choice he would like to bring down the cost of Green H2 to 1 USD a kg and it is possible given the fact that India imports185 Billion USD on toxic fossil fuels – crude and our consumption rate is increasing 3 times than that of the developed nations. At this rate we will touch 200 billion USD imports very soon putting a lot of pressure on our exchequer.
If we divert this fund to make Green hydrogen , then we can put all our might to get a cheaper green hydrogen.
I totally agree with his views – given the current challenges of Huge crude imports bill and that too with a lot of uncertainty Due to geopolitical situations and crude price volatility, it makes a lot of sense- we have all ingredients to make green hydrogen a sustainable future fuel – we are perhaps the only nation in the world – lucky to be blessed by Mother Nature with year round Sun light , wind , Water and vast Land Mass to put up solar plants , wind mills both on shore and off shore – we are surrounded by sea from all around .And we have no dearth of human talents.

Hope the Minister will walk the talk if Modi 3 comes to power…and it makes sense since both the dual challenge of meeting carbon emission and at the same time Self reliance – Atma Nirbhar Bharat…
However , for now , what initiatives have already been taken is only a trailer – full movy yet to be played

Annual Report 2023 | CPHI Global

CPHI Annual Report, Oct 2023

Broad Points from report:
^ The 2022, mark a watershed moment in India’s rise in reputation of biologics production – notably, Covid vaccines, the Serum Institute, Bharat biotech, Biocon and, on the CDMO side, Syngene helping transform the country’s reputation.
^ The outlook for India into 2024 continues to look very strong and overall, the best of any market in the survey.
^ India is already supplying much of world generics demand: including 50% of drugs in Africa, 40% in the USA and around 25% in the UK, but what we are now seeing is a gradual shift in India toward high value drugs driven in part by the fact that there simply aren’t enough facilities in the west to support its innovation engine and desires to build these have cooled in an inflationary, low capital environment.
^ India is well known to have highly capable IT workforce and we may in fact see a convergence of interest between India’s two largest export industries (pharma and IT).
^ India has by far the world largest ‘naive patient’ base for clinical trials. This coupled with the country’s prestigious pharmaceutical manufacturing could indeed be an incredibly attractive combination for many of the world’s largest innovators.
^ India’s stellar IT prowess positions it as a potential leader in AI driven pharma innovations. With the world’s most extensive ‘naive patient’ base for clinical trials, the confluence of India’s pharmaceutical and IT sectors could make it a global epicentre for secondary data analysis using AI.
^ India to continue to invest in newer biologics technologies is that CDMOs here are typically operating EBITA margins as high as 35% verses just 20% in the west.
^ Majority of analysts state that on average biosimilar development takes just 3-5 years in India verses 7 in the West and costs on average 10X less – with prices as low as £10million in some cases.
^ India will now see the fastest rates of overall growth in biologicals in the next 5-years.

Persistent Systems

Sales Growth(18%) has been falling with rate ~ PAT Growth

BFSI (High Interest Rates) is still falling with Healthcare coming to the rescue. However EBIT in Healthcare is surprisingly lower despite similar margins.

P/E of 50 for growth rate of 16% is slightly on higher side.

It would be the amount of loans disbursed against those pledged shares ie @ 1777 cr